Glendon French III Sells 41,882 Shares of Pulmonx (NASDAQ:LUNG) Stock

Pulmonx Corporation (NASDAQ:LUNG) CEO Glendon French III sold 41,882 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $2.26, for a total value of $94,653.32. Following the transaction, the chief executive officer owned 1,137,936 shares of the company’s stock, valued at approximately $2,571,735.36. This represents a 3.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Pulmonx Stock Down 2.2%

Shares of LUNG opened at $2.21 on Friday. The firm has a market cap of $94.92 million, a P/E ratio of -1.91 and a beta of 0.34. Pulmonx Corporation has a 12-month low of $1.13 and a 12-month high of $2.89. The company’s 50-day moving average price is $1.82 and its 200 day moving average price is $1.57. The company has a current ratio of 4.32, a quick ratio of 3.52 and a debt-to-equity ratio of 0.95.

Pulmonx (NASDAQ:LUNG) last posted its earnings results on Wednesday, July 29th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. Pulmonx had a negative net margin of 55.03% and a negative return on equity of 96.66%. The company had revenue of $22.76 million for the quarter, compared to analysts’ expectations of $22.39 million. On average, sell-side analysts forecast that Pulmonx Corporation will post -1.05 earnings per share for the current year.

Institutional Trading of Pulmonx

Hedge funds have recently made changes to their positions in the business. Stonepine Capital Management LLC purchased a new stake in Pulmonx during the 2nd quarter worth approximately $1,060,067. Parkman Healthcare Partners LLC purchased a new position in Pulmonx in the 2nd quarter valued at approximately $841,000. ADAR1 Capital Management LLC purchased a new position in Pulmonx in the 2nd quarter valued at approximately $526,000. Deutsche Bank AG acquired a new position in shares of Pulmonx in the second quarter worth $523,000. Finally, Primecap Management Co. CA acquired a new position in shares of Pulmonx in the second quarter worth $5,996,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

Pulmonx News Roundup

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Analyst sentiment remains broadly favorable, with three Buy ratings and one Sell rating producing a “Moderate Buy” consensus. The average price target of $7.67 is substantially above recent trading levels, suggesting significant potential upside if Pulmonx delivers on its growth plans. Pulmonx analyst and earnings information
• Positive Sentiment: Pulmonx’s latest quarterly results exceeded expectations: revenue was $22.76 million versus the $22.39 million consensus estimate, while its loss of $0.24 per share was narrower than the expected $0.28 loss. Pulmonx quarterly results
• Neutral Sentiment: CEO Glendon French III, General Counsel David Lehman, Geoffrey Rose and Srikanth Radhakrishnan sold a combined 78,340 shares at approximately $2.26 per share. The filings say the transactions covered tax-withholding obligations related to vested equity awards, reducing their significance as a signal of declining confidence; however, the sales may add modest short-term supply. Pulmonx insider sales report
• Negative Sentiment: Recent gains have triggered profit-taking, contributing to the stock’s retreat and weakening short-term trading sentiment. Pulmonx shares fall following recent gains
• Negative Sentiment: Pulmonx remains unprofitable, and analysts expect a full-year loss of roughly $1.05 per share. The company’s negative margins and uncertain path to sustained profitability are keeping investors cautious despite the earnings beat. Pulmonx profit-taking and earnings outlook

Analyst Upgrades and Downgrades

Several research firms recently weighed in on LUNG. Weiss Ratings upgraded shares of Pulmonx from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 25th. Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.67.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.